Genomics & Epigenomics

The main objective of this SP is to use large-scale analyses of clinical samples (canceromics) to identify candidate biomarkers in cancer. The analyses involve genomic sequencing, studies of DNA methylation, and genome and transcriptome microarrays.

Central activities in this programme are the following:

• Determination of early and late events in tumourigenesis.

• Subclassification of tumour staging with prognostic/therapeutic impact.

• Assessment of tumour heterogeneity.

• Identification of markers of metastatic processes.

• Identification of prognostic impact of genome changes.

• Identification of novel fusion oncogenes.

• Identification of novel master keys in cancer.